Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Meng, Weixu ^a,b   Pan, Weiqi ^a,b   Zhang, Anna J X ^c   Li, Zhengfeng ^a,b   Wei, Guowei ^a   Feng, Liqiang ^a,b   Dong, Zhenyuan ^a,b   Li, Chufang ^b   Hu, Xiangjing ^a   Sun, Caijun ^a,b   Luo, Qinfang ^b   Yuen, Kwok Yung ^c   Zhong, Nanshan ^b   Chen, Ling ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HEMAGGLUTININ; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1H10; MONOCLONAL ANTIBODY 4D5; MONOCLONAL ANTIBODY 4E6; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BODY WEIGHT; CLADISTICS; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; GENOME ANALYSIS; HEMAGGLUTINATION INHIBITION TEST; HISTOPATHOLOGY; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; LUNG INJURY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PANDEMIC; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE DISPLAY; PROTECTION; RHESUS MONKEY; SEQUENCE HOMOLOGY; SURFACE PLASMON RESONANCE; VIRUS LOAD; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS VIRULENCE; ANIMAL; BIOSYNTHESIS; COMMUNICABLE DISEASES, EMERGING; EPIDEMIC; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MOUSE;

MACACA MULATTA; MUS; ORTHOMYXOVIRIDAE; SARS CORONAVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MACACA MULATTA; MICE;

EID: 84879167987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066276     Document Type: Article

References (43)

1. Zhou B, Zhong N, Guan Y, (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357(14):: 1450-1451. doi:10.1056/NEJMc070359. PubMed: 17914053.
2. Hung IF, To KK, Lee CK, Lee KL, Chan K, et al. (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52(4):: 447-456. doi:10.1093/cid/ciq106. PubMed: 21248066.
3. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105(16):: 5986-5991. doi:10.1073/pnas.0801367105. PubMed: 18413603.
4. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195):: 667-671. doi:10.1038/nature06890. PubMed: 18449194.
5. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, et al. (2009) Cross-Protective Potential of a Novel Monoclonal Antibody Directed against Antigenic Site B of the Hemagglutinin of Influenza A Virus. PLOS Pathog 5(3):: e1000350.
6. Sun L, Lu X, Li C, Wang M, Liu Q, et al. (2009) Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies against Influenza A H5N1 viruses. PLOS ONE 4(5):: e5476. doi:10.1371/journal.pone.0005476. PubMed: 19421326.
7. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard Pet al. (2008) Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells. PLOS ONE 3(12):: e3942. doi:10.1371/journal.pone.0003942. PubMed: 19079604.
8. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, et al. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455(7212):: 532-536. doi:10.1038/nature07231. PubMed: 18716625.
9. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16(3):: 265-273. doi:10.1038/nsmb.1566. PubMed: 19234466.
10. Corti D, Suguitan Pinna D Jr, Pinna D, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120(5):: 1663-1673. doi:10.1172/JCI41902. PubMed: 20389023.
11. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLOS Med 4(5):: e178. doi:10.1371/journal.pmed.0040178. PubMed: 17535101.
12. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924):: 246-251. doi:10.1126/science.1171491. PubMed: 19251591.
13. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044):: 850-856. doi:10.1126/science.1205669. PubMed: 21798894.
14. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, et al. (2012) High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 4(142):: 142-196. PubMed: 22786681.
15. Rhesus macaque genome sequencing and analysis consortium, et al. (2007) Evolutionary and biomedical insights from the rhesus macaque genome. Science 316(5822): 222-234.
16. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO WHO website. Available at http://www.who.int/influenza/human_animal_interface/EN_GIP_20120706CumulativeNumberH5N1cases.pdf. Accessed 2012.
17. de Jong MD, Tran TT, Khanh TH, Hien VM, Smith GJD, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353(25):: 2667-2672. doi:10.1056/NEJMoa054512. PubMed: 16371632.
18. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, et al. (2008) Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105(23):: 8091-8096. doi:10.1073/pnas.0711942105. PubMed: 18523003.
19. Hu X, Meng W, Dong Z, Pan W, Sun C, et al. (2011) Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice. Virus Res 155(1):: 156-162. doi:10.1016/j.virusres.2010.09.014. PubMed: 20883733.
20. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329(5995):: 1060-1064. doi:10.1126/science.1192517. PubMed: 20647428.
21. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367(9509):: 475-481. doi:10.1016/S0140-6736(06)68076-8. PubMed: 16473124.
22. Bible JM, Howard W, Robbins H, Dunn-Walters DK, (2003) IGHV1, IGHV5 and IGHV7 subgroup genes in the Rhesus macaque. Immunogenetics 54(12):: 867-873. PubMed: 12671738.
23. Helmuth EF, Letvin NL, Margolin DH, (2000) Germline repertoire of the immunoglobulin V(H)3 family in rhesus monkeys. Immunogenetics 51(7):: 519-527. doi:10.1007/s002510000170. PubMed: 10912503.
24. Andris JS, Miller AB, Abraham SR, (1997) Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: Predominance of the VH4 family but not VH4-21 (V4-34). Mol Immunol 34(3):: 237-253. doi:10.1016/S0161-5890(97)00021-7. PubMed: 9224966.
25. Link JM, Hellinger MA, Schroeder HW, (2002) The Rhesus monkey immunoglobulin IGHD and IGHJ germline repertoire. Immunogenetics 54(4):: 240-250. doi:10.1007/s00251-002-0468-2. PubMed: 12136335.
26. Howard WA, Bible JM, Finlay-Dijsselbloem E, Openshaw S, Dunn-Walters DK, (2005) Immunoglobulin light-chain genes in the rhesus macaque I: Kappa light-chain germline sequences for subgroups IGKV1, IGKV and IGKV3. Immunogenetics 57(3-4):: 210-218. doi:10.1007/s00251-005-0794-2. PubMed: 15900492.
27. Howard WA, Bibke JM, Finlay-Dijsselbloem E, Openshaw S, Dunn-Walters DK, (2005) Immunoglobulin light-chain genes in the rhesus macaque. p. pp. II: lambda light-chain germline sequences for subgroups IGLV1, IGLV2, IGLV3, IGLV4 and IGLV5. Immunogenetics 57(9):655-664.
28. Rhesus macaque Immunoglobulin gene database website Avalable: http://www.kcl.ac.uk/immunobiology/Mac_ig/index.html Accessed 2013.
29. Spencer J, Dunn M, Dunn-Walters DK, (1999) Characterization of the Three Immunoglobulin G Subclasses of Macaques. Scand J Immunol 49(6):: 595-610. doi:10.1046/j.1365-3083.1999.00540.x. PubMed: 10354371.
30. Margolin DH, Saunders EH, Bronfin B, de Rosa N, Axthelm MK, et al. (2006) Germinal center function in the spleen during simian HIV infection in rhesus monkeys. J Immunol 177(2):: 1108-1119. PubMed: 16818768.
31. Scinicariello F, Engleman CN, Jayashankar L, Mcclure HM, Attanasio R, (2004) Rhesus macaque antibody molecules: Sequences and heterogeneity of alpha and gamma constant regions. Immunology 111(1):: 66-74. doi:10.1111/j.1365-2567.2004.01767.x. PubMed: 14678200.
32. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, et al. (2008) Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384(5):: 1400-1407. doi:10.1016/j.jmb.2008.10.033. PubMed: 18976662.
33. Hwang WY, Foote J, (2005) Immunogenicity of engineered antibodies. Methods 36(1):: 3-10. doi:10.1016/j.ymeth.2005.01.001. PubMed: 15848070.
34. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, et al. (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 18(7):: 1216-1223. doi:10.1093/annonc/mdm114. PubMed: 17470451.
35. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC, et al. (2003) Allergic asthma and an anti-CD23 mAb (IDEC-152): Results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 112(3):: 563-570. doi:10.1016/S0091-6749(03)01861-X. PubMed: 13679816.
36. Pelat T, Thullier P, (2009) Non-human primate immune libraries combined with germline humanization. mAbs 1(4):1-5.
37. De Marco D, Clementi N, Mancini N, Solforosi L, Moreno GJ, et al. (2012) A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLOS ONE 7(4):: e34415. doi:10.1371/journal.pone.0034415. PubMed: 22496802.
38. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, et al. (1999) Rescue of Influenza A Virus from Recombinant DNA. J Virol 73(11):: 9679-9682. PubMed: 10516084.
39. Bradbury ARM, Marks JD, (2004) Phage Antibody Libraries. In: Clackso T, Lowman HB, eds. Phage Display. Oxford: Oxford University Press. pp. pp. 243-288.
40. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avain influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37(4):: 917-943.
41. Kendal AP, Skehel JJ, Pereira MS, (1982) World Health Organization Collaborating Centers for Reference and Research on Infl{ligature}uenza: concepts and procedures for laboratory-based infl{ligature}uenza surveillance. World Health Organization Collaborating Centers for Reference and Research in Infl{ligature}uenza. Atlanta, Ga.: Centers for Disease Control. pp. pp. B17-B35.
42. Lambkin R, McLain L, Jones SE, Aldridge SL, Dimmock NJ, (1994) Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: A possible mechanism for antigenic drift. J Gen Virol 75(Pt 12): 3493-3502. doi:10.1099/0022-1317-75-12-3493. PubMed: 7527838.
43. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, et al. (2008) Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105(23):: 8091-8096. doi:10.1073/pnas.0711942105. PubMed: 18523003.